INDEMNIFICATION AGREEMENTIndemnification Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [____________] between Sagimet Biosciences Inc., a Delaware corporation (the “Company”), and [______________] (“Indemnitee”).
LEASE AGREEMENT between Casiopea Bovet, LLC “Landlord” and 3-V Biosciences, Inc., a Delaware corporation “Tenant”Lease Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations
Commencement Date: The Lease shall commence upon the later of substantial completion of the Tenant Improvements by Landlord or April 1, 2019.
investors’ rights agreementInvestors’ Rights Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of December 21, 2020, by and among Sagimet Biosciences Inc., a Delaware corporation (the “Company”), and the investors listed on the Schedule of Investors attached as Exhibit A hereto (each, an “Investor,” and collectively, the “Investors”).
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between and Ascletis BioScience Co. Ltd. Dated January 18, 2019Exclusive License and Development Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Hong Kong
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is executed as of January 18, 2019 by and between 3-V Biosciences, Inc., a corporation organized under the laws of Delaware (“3-V”), having a principal place of business at 3715 Haven Ave. Suite 220, Menlo Park, CA 94025, and Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技（杭州）有限公司), a corporation under the laws of China having a registered office at Room 1102，Building D，198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou, China (“Ascletis”). 3-V and Ascletis are sometimes collectively referred to herein as the “Parties” or individually as a “Party”.
Patent Assignment AgreementPatent Assignment Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Hong Kong
This Patent Assignment Agreement (this “Agreement”), effective as of October 25, 2019, is signed by and between Sagimet Biosciences Inc. (formerly known as 3-V Biosciences, Inc.), a corporation organized under the laws of Delaware, having a principal place of business at 155 Bovet Road Suite 303, San Mateo, CA 94402 (hereinafter referred as “Assignor” or “Sagimet”); and Gannex Pharma Co., Ltd. ( 甘莱制药有限公司), an affiliate of Ascletis BioScience Co., Ltd. (both wholly-owned subsidiaries of Ascletis Pharma Inc.) and a corporation under the laws of China having a registered office at No. 665 Zhangjiang Road, 3rd Floor, Shanghai Pilot Free Trade Zone, Shanghai, China (hereinafter referred to as "Assignee").
ContractStock Option Agreement • April 16th, 2021 • Sagimet Biosciences Inc. • Pharmaceutical preparations • Delaware
